Education
About Us
Working with TipRanks
Follow Us
Indivior PLC (INDV)
NASDAQ:INDV
INDV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.33 - $25.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.75M
Market Cap
£3.03B
Enterprise Value$1.71B
Total Cash (Recent Filing)£510.00M
Total Debt (Recent Filing)£366.00M
Price to Earnings (P/E)34.3
Beta0.60
Next Earnings
Oct 23, 2025EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding124,769,820
10 Day Avg. Volume2,254,614
30 Day Avg. Volume3,746,243
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£18.13Price Target Upside-24.50% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial StabilityIndivior is well-positioned to fund any legal obligations, reinvest in its lead assets, and pursue share repurchases or accretive transactions with $538M in cash and investments.
Leadership And Growth PotentialIndivior's established leadership in the OUD sector and the potential for significant growth in the LAI category could see both Sublocade and Brixadi flourish.
Operational EfficiencyThe company achieved significant opex savings, contributing to the group sales beat expectations by 9%, gross margin by 10%, and adj. EBIT by over 40%.
Bears Say
Competitive PressureSublocade was ultimately $100M below initial 2024 guidance from competitor Brixadi share gains and also CJS funding disruption.
Market HeadwindsCJS funding gaps remain a key headwind, affecting Sublocade sales and contributing to a 38% decline in the CJS market.
Spending And EfficiencyThe company is believed to be overspending on G&A, and the operational structure could become much more efficient, enhancing future profitability.
Indivior News
INDV FAQ
What was Indivior PLC’s price range in the past 12 months?
Indivior PLC lowest stock price was $7.33 and its highest was $25.00 in the past 12 months.
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is £3.03B.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Oct 23, 2025 which is in 52 days.
How were Indivior PLC’s earnings last quarter?
Indivior PLC released its earnings results on Jul 31, 2025. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.25.
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Overvalued.
Does Indivior PLC pay dividends?
Indivior PLC does not currently pay dividends.
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate is 0.39.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 124,769,820 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Indivior PLC reported an EPS of $0.51 in its last earnings report, beating expectations of $0.26. Following the earnings report the stock price went up 16.092%.
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in INDV
Company Description
Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
INDV Company Deck
INDV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Indivior's record-breaking performance with SUBLOCADE, upwardly revised financial guidance, and strategic initiatives to streamline operations and improve execution. However, challenges such as pricing pressure on SUBOXONE Film and opportunities for improvement in U.S. commercial execution were acknowledged. Despite these challenges, the overall sentiment leans towards the positive due to the significant achievements and strategic roadmap.View all INDV earnings summariesINDV Stock 12 Month Forecast
Average Price Target
$18.13
▼(-24.50% Downside)
Technical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Ownership Overview
4.95% Insiders
3.90% Mutual Funds
49.83% Other Institutional Investors
36.38% Public Companies and
Individual Investors